Welcome to our dedicated page for OptiNose news (Ticker: OPTN), a resource for investors and traders seeking the latest updates and insights on OptiNose stock.
OptiNose, Inc. (NASDAQ: OPTN), founded in 2010 and headquartered in Yardley, Pennsylvania, is a global specialty pharmaceutical company focused on improving the lives of patients treated by ear, nose, and throat (ENT) and allergy specialists. The company is known for its innovative approach to pharmaceutical development and commercialization, aiming to offer value to both the healthcare system and its stakeholders.
OptiNose's flagship product is XHANCE (fluticasone propionate) nasal spray, a unique therapeutic that utilizes the proprietary Exhalation Delivery System (EDS). This system delivers a topical corticosteroid deep into the nasal passages to treat chronic rhinosinusitis with nasal polyps. Unlike traditional nasal sprays, XHANCE targets inflammation high and deep within the nasal passages, reaching areas previously inaccessible by standard treatments.
Recently, XHANCE was approved by the FDA for the treatment of chronic rhinosinusitis without nasal polyps, expanding its potential patient base significantly. This approval was backed by robust clinical data from the ReOpen program, consisting of two global, randomized, double-blind, placebo-controlled Phase 3 trials. These trials demonstrated significant improvement in both symptoms and inflammation for patients with chronic sinusitis, with or without nasal polyps. Some common adverse reactions included epistaxis, headache, and nasopharyngitis, consistent with its labeled safety profile.
OptiNose continues to innovate, working on faster and cost-effective product developments and exploring new commercial models. The company collaborates with ENT and allergy specialists to bring breakthrough treatments to patients, focusing on efficiency and effectiveness in all its operations. OptiNose's commitment to values and ethical practices ensures their dedication to patient care and improved health outcomes.
For the latest updates and detailed information on OptiNose's financial performance, current projects, and strategic developments, visit their website or follow them on social media platforms like X and LinkedIn.
Optinose reported a 79% increase in XHANCE net revenue for Q2 2021, totaling $18.4 million, compared to Q2 2020. Total prescriptions rose by 33%, and new prescriptions surged by 55%. The company has completed enrollment in the first pivotal chronic sinusitis clinical trial and aims for at least $80 million in XHANCE revenue for 2021. Net loss for Q2 2021 was $23.5 million ($0.44 per share). Optinose has cash equivalents of $93.9 million as of June 30, 2021.
Optinose (NASDAQ:OPTN) announced the successful completion of recruitment in its first pivotal clinical trial for XHANCE, a nasal spray aimed at treating chronic sinusitis, with top-line results expected in Q1 2022. This milestone brings the company closer to potentially offering the first FDA-approved drug treatment for the estimated 30 million chronic sinusitis sufferers in the U.S. The company is focusing its efforts on completing the second pivotal trial by year-end. CEO Peter Miller emphasized the significant market potential for XHANCE with successful development.
Optinose reported preliminary XHANCE net revenue of $18.4 million for Q2 2021, marking a 79% increase year-over-year and a 67% increase from Q1 2021. XHANCE prescriptions rose 33% to 82,900, with revenue per prescription increasing 35% to $221. The company maintains its 2021 revenue guidance of at least $80 million. Full financial results will be disclosed on August 11, 2021, during a scheduled conference call.
Optinose (NASDAQ:OPTN) announced the publication of a new treatment algorithm for chronic rhinosinusitis with nasal polyps in the International Forum of Allergy & Rhinology. The algorithm promotes Exhalation Delivery System-fluticasone (EDS-FLU) as a key treatment step, simplifying the confusion surrounding available treatment options. With over 85% of patients frustrated by standard steroids, EDS-FLU aims to provide better symptom relief. This algorithm is expected to enhance care quality and guide clinical decision-making amidst increasing treatment choices.
Optinose (NASDAQ:OPTN), a pharmaceutical company specializing in ENT and allergy treatments, has announced that CEO Peter Miller will present a company overview at the Jefferies Virtual Healthcare Conference on June 3, 2021, at 3:30 p.m. ET. The public can access the presentation via the Investors page on the Optinose website. Additionally, a replay of the webcast will be available for 30 days post-event. For more details about Optinose and its services, visit www.optinose.com.
Optinose (NASDAQ:OPTN) reported a total revenue of $12.0 million for Q1 2021, boosted by XHANCE net revenues of $11.0 million, a 55% increase from Q1 2020. The number of XHANCE prescriptions surged by 30% to 72,600, while new prescriptions rose by 16% to 25,900. Despite this growth, the company reported a net loss of $26.1 million, or $0.49 per share. Optinose anticipates XHANCE net revenues to reach at least $80 million for full-year 2021, with operating expenses expected between $137 million and $142 million.
Optinose (NASDAQ:OPTN) announced that it will release its first quarter 2021 financial results and corporate updates on May 5, 2021, before market open. A conference call led by the leadership team is scheduled for 8:00 a.m. Eastern Time on the same day. Additionally, CEO Peter Miller will present at the RBC Capital Markets Global Healthcare Conference on May 18, 2021, at 5:25 p.m. Eastern Time. Investors can access the conference call and the subsequent webcast on the company's website.
Optinose (NASDAQ:OPTN) announced that CEO Peter Miller will present a company overview and update at the Needham Virtual Healthcare Conference on April 15, 2021, at 11:45 a.m. ET. The presentation will be available for live streaming on the Optinose Investors page. A recorded version of the webcast will be accessible for 30 days post-event. As a global specialty pharmaceutical company, Optinose focuses on ENT and allergy treatments. For more details about Optinose and their offerings, visit their official website or follow them on social media.
FAQ
What is the current stock price of OptiNose (OPTN)?
What is the market cap of OptiNose (OPTN)?
What is OptiNose, Inc.?
What is XHANCE?
What recent approval did OptiNose receive from the FDA?
What is the ReOpen program?
What common side effects are associated with XHANCE?
How does OptiNose's Exhalation Delivery System (EDS) work?
What is chronic rhinosinusitis?
Where is OptiNose headquartered?
How does OptiNose create value for the healthcare system?
Where can I learn more about OptiNose and its products?
